Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Mar 2026

Wan Jinkai, Saatcioglu Hatice Duygu, Ellis Haley, Aguado-Fraile Elia, Xu Qin, Kondo Hiroshi, Manguso Robert T, Gritti Ilaria, Norden Bryanna L, Noble Carolina, Corcoran Ryan B, Lubner Sam J, Javle Milind, Abou-Alfa Ghassan K, Cleary James M, Kelley Robin K, Borad Mitesh J, Macarulla Teresa, Oh Do Youn, Daigle Scott, Gliser Camelia, Pandya Susan, Choe Sung, Tron Adriana E, Bardeesy Nabeel

Abstract excerpt

PURPOSE: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. EXPERIMENTAL DESIGN: We performed molecular profiling of matched baseline and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Circulating Tumor DNA

Share to Glycine

Share to Interferons

Share to Isocitrate Dehydrogenase

Share to MAP Kinase Signaling System

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 41460204
DOI: 10.1158/1078-0432.CCR-25-3284
PMCID: PMC13056288

Genes

IDH1
IDH2
ARID1A
KRAS
MAP2K1
NF1
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.PMID 41460204Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.Semantic proximity Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To DateSemantic proximity Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsSemantic proximity Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.Semantic proximity Read ↗

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic TargetingSemantic proximity Read ↗

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.